By Robin Foster HealthDay Reporter TUESDAY, Feb. 27, 2024 (HealthDay News) — For nearly a week, prescription drug orders have been disrupted at thousands of pharmacies as the largest health …
Risk Profile IDs COVID-19 Patients Who Will Benefit From Baricitinib
Baricitinib plus remdesivir linked to reduced risk of death, progression to invasive mechanical ventilation
Frexalimab Has Favorable Effect on Relapsing Multiple Sclerosis
Generally favorable effect seen in terms of number of new gadolinium-enhancing T1-weighted lesions at week 12
JNJ-77242113 Shows Greater Efficacy Than Placebo for Plaque Psoriasis
Percentage of patients with PASI-75 response was higher with the interleukin-23-receptor antagonist peptide
Meds Rarely Offered for COVID-19 Patients at High Risk for Progression
No reason other than mild symptoms given for almost half of patients at high risk for progression who were not offered treatment
Simnotrelvir Shortens Time to Resolution of Symptoms in COVID-19
On day 5, the decrease in viral load from baseline was greater in the simnotrelvir group versus placebo group
New Rx for Schedule-II Stimulants for ADHD Increased During Pandemic
No significant changes seen in new prescriptions for antidepressants, benzodiazepines, or buprenorphine for opioid use disorder
SARS-CoV-2 Rebound Rate Similar With, Without Oral Antivirals
Second study shows similar rates of SARS-CoV-2 RNA shedding and viral rebound for those receiving nirmatrelvir/ritonavir or placebo
Fluvoxamine Does Not Shorten Duration of COVID-19 Symptoms
Findings observed among adults with mild or moderate COVID-19
Maintenance Immunosuppressive Drugs Tied to Severe COVID-19
Findings seen for recipients across solid organ transplant types